Profile: Exelixis Inc (EXEL.O)
20 Oct 2016
Exelixis, Inc., incorporated on November 15, 1994, is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. The Company is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). The Company's other products are Cobimetinib and XL888.
Cabozantinib inhibits the activity of tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors, MET, AXL and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes, such as oncogenesis, metastasis, tumor angiogenesis and maintenance of the tumor microenvironment. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer (MTC), and is marketed under the brand name COMETRIQ.
Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. The Company is engaged in development and commercialization of Cobimetinib in collaboration with Genentech. Cobimetinib is commercially available in the United States for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib, where it is marketed as COTELLIC for that use. COTELLIC is also approved in the European Union and Switzerland for the treatment of people with BRAF V600 mutation-positive advanced melanoma.
XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins, including kinases, such as BRAF, MET and vascular endothelial growth factor receptor 2 (VEGFR2), which are implicated in cancer cell proliferation and survival. The Company has completed Phase I clinical trials for XL888 and focuses on conducting Phase Ib IST of the triple combination of Vemurafenib, Cobimetinib and XL888.
The Company has established collaborations with other pharmaceutical and biotechnology companies for various compounds and programs in its portfolio. The Company has collaborations with GlaxoSmithKline to discover and develop therapeutics in the areas of vascular biology, inflammatory disease and oncology. It has collaborations with Bristol-Myers Squibb for the discovery, development and commercialization of therapies targeted against LXR a nuclear hormone receptor implicated in cardiovascular and metabolic disorders. The Company has an agreement with Sanofi for SAR245408 and SAR245409 inhibitors of phosphoinositide 3 kinase (PI3K) and collaboration for the discovery of inhibitors of PI3K for the treatment of cancer. The Company entered into an agreement with Merck for PI3Kdelta program, including XL499 and other related compounds. The Company has collaboration with Daiichi Sankyo for the discovery, development and commercialization of therapies targeted against the mineralocorticoid receptor a nuclear hormone receptor implicated in a range of cardiovascular and metabolic diseases.
The Company competes with AstraZeneca, Bayer, Amgen, Pfizer, Ariad Pharmaceutical, Novartis and Eisai.
210 E Grand Ave
SOUTH SAN FRANCISCO CA 94080-4811
Company Web Links
- BRIEF-Exelixis announces positive results from phase 2 CABOSUN trial of Cabozantinib vs Sunitinib
- BRIEF-Ipsen and Exelixis announce positive results from Phase 2 CABOSUN trial of cabozantinib
- BRIEF-Exelixis announces Phase 1 trial results for Cabozantinib in combination with Nivolumab in advanced Genitourinary tumors
- BRIEF-Exelixis elects Julie Anne Smith to board
- BRIEF-Exelixis announces redemption of remaining 4.25 convertible senior subordinated notes